{
  "topic": {
    "en": "Ventricular Fibrillation (VF)",
    "zh": "心室顫動"
  },
  "definition": {
    "en": "Ventricular fibrillation is a life-threatening cardiac arrhythmia characterized by completely disorganized, chaotic electrical activity in the ventricles, resulting in ineffective ventricular contraction and no cardiac output. VF is a form of cardiac arrest requiring immediate intervention.",
    "zh": "心室顫動是一種危及生命的心律不整，特徵為心室電活動完全混亂、無組織，導致心室無法有效收縮，沒有心輸出量。VF 是心臟驟停的一種形式，需要立即介入處理。"
  },
  "ecg_characteristics": {
    "en": "ECG Characteristics",
    "zh": "心電圖特徵",
    "general": {
      "rate": {
        "en": "300-500 bpm (unmeasurable)",
        "zh": "300-500 bpm（無法測量）"
      },
      "rhythm": {
        "en": "Grossly irregular, chaotic",
        "zh": "節律完全混亂、無規則"
      },
      "p_waves": {
        "en": "Absent",
        "zh": "無 P 波"
      },
      "qrs_complex": {
        "en": "No identifiable QRS, irregular morphology",
        "zh": "QRS 無法辨識、形態不規則"
      }
    },
    "types": [
      {
        "type": "coarse_vf",
        "name": {
          "en": "Coarse VF",
          "zh": "粗顫動（Coarse VF）"
        },
        "description": {
          "en": "Larger amplitude, early phase. Better response to defibrillation.",
          "zh": "振幅較大，屬於早期階段。對電擊去顫反應較佳。"
        }
      },
      {
        "type": "fine_vf",
        "name": {
          "en": "Fine VF",
          "zh": "細顫動（Fine VF）"
        },
        "description": {
          "en": "Smaller amplitude, prolonged phase. May be confused with asystole.",
          "zh": "振幅較小，屬於延長階段。可能與心搏停止（asystole）混淆。"
        }
      }
    ]
  },
  "etiology": {
    "en": "Etiology",
    "zh": "病因",
    "primary": {
      "en": "Idiopathic (Primary)",
      "zh": "原發性（Idiopathic）",
      "category": {
        "en": "Genetic/Channelopathies",
        "zh": "遺傳性離子通道病變"
      },
      "items": [
        {
          "en": "Long QT Syndrome (LQTS)",
          "zh": "長 QT 症候群（Long QT Syndrome）"
        },
        {
          "en": "Brugada Syndrome",
          "zh": "布魯格達症候群（Brugada Syndrome）"
        },
        {
          "en": "Catecholaminergic Polymorphic VT (CPVT)",
          "zh": "兒茶酚胺敏感性多型性心室頻脈（CPVT）"
        },
        {
          "en": "Short QT Syndrome",
          "zh": "短 QT 症候群（Short QT Syndrome）"
        }
      ]
    },
    "secondary": {
      "en": "Disease-Induced (Secondary)",
      "zh": "疾病誘導（Secondary）",
      "structural_heart_disease": {
        "en": "Structural Heart Disease",
        "zh": "結構性心臟疾病",
        "items": [
          {
            "en": "Ischemic Cardiomyopathy / MI (Scar tissue)",
            "zh": "缺血性心肌病變 / 心肌梗塞（疤痕組織）"
          },
          {
            "en": "Hypertrophic Cardiomyopathy (HCM) - Disorganized fibers",
            "zh": "肥厚性心肌病變（HCM）— 纖維排列紊亂"
          },
          {
            "en": "Dilated Cardiomyopathy (DCM) - Stretched myocardium",
            "zh": "擴張性心肌病變（DCM）— 心肌過度伸展"
          },
          {
            "en": "Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)",
            "zh": "致心律失常性右心室心肌病變（ARVC）"
          }
        ]
      },
      "electrolyte_abnormalities": {
        "en": "Electrolyte Abnormalities",
        "zh": "電解質異常",
        "items": [
          {
            "en": "Hypokalemia (Prolongs repolarization)",
            "zh": "低血鉀（延長再極化）"
          },
          {
            "en": "Hyperkalemia (Depresses conduction)",
            "zh": "高血鉀（抑制傳導）"
          },
          {
            "en": "Hypomagnesemia (Predisposes to afterdepolarizations)",
            "zh": "低血鎂（易導致後去極化）"
          }
        ]
      },
      "metabolic_systemic_factors": {
        "en": "Metabolic & Systemic Factors",
        "zh": "代謝與全身性因素",
        "items": [
          {
            "en": "Acidosis",
            "zh": "酸中毒"
          },
          {
            "en": "Hypoxemia",
            "zh": "低血氧"
          },
          {
            "en": "Hypothermia",
            "zh": "低體溫"
          }
        ]
      }
    }
  },
  "clinical_presentation": {
    "en": "Clinical Presentation (Pulseless Arrest)",
    "zh": "臨床表現（無脈搏心臟驟停）",
    "warning": {
      "en": "IMMEDIATE INTERVENTION REQUIRED. VF = CARDIAC ARREST",
      "zh": "需立即介入處理。VF = 心臟驟停"
    },
    "signs": [
      {
        "en": "Sudden loss of consciousness (within seconds)",
        "zh": "突然意識喪失（數秒內）"
      },
      {
        "en": "No pulse",
        "zh": "無脈搏"
      },
      {
        "en": "No blood pressure",
        "zh": "無血壓"
      },
      {
        "en": "Agonal respirations or apnea",
        "zh": "瀕死呼吸或呼吸停止"
      },
      {
        "en": "Found unresponsive (if unwitnessed)",
        "zh": "發現時已無反應（若未目擊）"
      }
    ]
  },
  "treatment": {
    "overview": {
      "en": "Management of Ventricular Fibrillation (ACLS Protocol)",
      "zh": "心室顫動處置（ACLS 流程）"
    },
    "immediate_actions": {
      "en": "Immediate Actions",
      "zh": "緊急處置",
      "steps": [
        {
          "step": 1,
          "en": "Call for help & activate EMS",
          "zh": "呼救並啟動緊急醫療系統"
        },
        {
          "step": 2,
          "en": "Start CPR",
          "zh": "開始心肺復甦術（CPR）"
        },
        {
          "step": 3,
          "en": "Defibrillation (Shock) ASAP",
          "zh": "儘速電擊去顫"
        }
      ],
      "note": {
        "en": "Time is critical for survival",
        "zh": "時間對存活率至關重要"
      }
    },
    "defibrillation": {
      "en": "Defibrillation - The Definitive Treatment",
      "zh": "電擊去顫 — 決定性治療",
      "energy_settings": {
        "title": {
          "en": "Energy Settings",
          "zh": "電擊能量設定"
        },
        "biphasic": {
          "en": "120-200 J (device-specific)",
          "zh": "120-200 焦耳（依機型而定）"
        },
        "monophasic": {
          "en": "360 J",
          "zh": "360 焦耳"
        }
      },
      "protocol": {
        "title": {
          "en": "Protocol",
          "zh": "處理流程"
        },
        "steps": [
          {
            "en": "Defibrillate AS SOON AS VF is identified",
            "zh": "一旦確認 VF 立即電擊"
          },
          {
            "en": "Resume CPR IMMEDIATELY after shock",
            "zh": "電擊後立即恢復 CPR"
          }
        ]
      }
    },
    "high_quality_cpr": {
      "en": "High-Quality CPR",
      "zh": "高品質心肺復甦術",
      "parameters": [
        {
          "parameter": "rate",
          "en": "Rate: 100-120 compressions/minute",
          "zh": "速率：每分鐘 100-120 次按壓"
        },
        {
          "parameter": "depth",
          "en": "Depth: At least 5 cm (2 inches)",
          "zh": "深度：至少 5 公分（2 英寸）"
        },
        {
          "parameter": "recoil",
          "en": "Allow full chest recoil",
          "zh": "允許胸廓完全回彈"
        },
        {
          "parameter": "interruptions",
          "en": "Minimize interruptions",
          "zh": "盡量減少中斷"
        }
      ]
    },
    "pharmacotherapy": {
      "en": "Pharmacotherapy",
      "zh": "藥物治療",
      "agents": [
        {
          "drug": "Epinephrine",
          "dose": {
            "en": "1 mg IV/IO",
            "zh": "1 mg IV/IO"
          },
          "timing": {
            "en": "Every 3-5 minutes",
            "zh": "每 3-5 分鐘"
          }
        },
        {
          "drug": "Amiodarone",
          "dose": {
            "en": "300 mg IV/IO first dose; 150 mg second dose",
            "zh": "首劑 300 mg IV/IO；第二劑 150 mg"
          },
          "timing": {
            "en": "After 2-3 shocks",
            "zh": "在 2-3 次電擊後給予"
          },
          "note": {
            "en": "Significantly improves survival to hospital admission",
            "zh": "顯著增加到院存活率"
          }
        },
        {
          "drug": "Lidocaine",
          "dose": {
            "en": "1-1.5 mg/kg first dose; 0.5-0.75 mg/kg subsequent",
            "zh": "首劑 1-1.5 mg/kg；後續劑量 0.5-0.75 mg/kg"
          },
          "timing": {
            "en": "Alternative to amiodarone",
            "zh": "作為 Amiodarone 的替代選擇"
          }
        }
      ]
    },
    "reversible_causes": {
      "en": "Address Reversible Causes (H's and T's)",
      "zh": "評估與矯正可能誘發 VF 的因素（H's and T's）",
      "h_causes": {
        "en": "H's",
        "zh": "H's（五個 H）",
        "items": [
          {
            "en": "Hypovolemia",
            "zh": "低血容量（Hypovolemia）"
          },
          {
            "en": "Hypoxia",
            "zh": "缺氧（Hypoxia）"
          },
          {
            "en": "Hydrogen ion (acidosis)",
            "zh": "酸中毒（Hydrogen ion / Acidosis）"
          },
          {
            "en": "Hypo/hyperkalemia",
            "zh": "低/高血鉀（Hypo/hyperkalemia）"
          },
          {
            "en": "Hypothermia",
            "zh": "低體溫（Hypothermia）"
          }
        ]
      },
      "t_causes": {
        "en": "T's",
        "zh": "T's（四個 T）",
        "items": [
          {
            "en": "Tension pneumothorax",
            "zh": "張力性氣胸（Tension pneumothorax）"
          },
          {
            "en": "Tamponade (cardiac)",
            "zh": "心包填塞（Cardiac tamponade）"
          },
          {
            "en": "Toxins",
            "zh": "毒物（Toxins）"
          },
          {
            "en": "Thrombosis (coronary or pulmonary)",
            "zh": "血栓（冠狀動脈或肺動脈）— 包含心肌梗塞與肺栓塞"
          }
        ]
      }
    }
  },
  "prevention": {
    "en": "Prevention of Ventricular Fibrillation",
    "zh": "心室顫動的預防",
    "primary_prevention": {
      "en": "Primary Prevention (High-risk patients without prior VF)",
      "zh": "初級預防（高風險但無 VF 病史的患者）",
      
      "indications_for_icd": {
        "en": "Indications for ICD Implantation",
        "zh": "植入式心律去顫器（ICD）適應症",
        "icd_role_title": {
          "en": "What Does ICD Do?",
          "zh": "ICD 的作用為何？"
        },
        "icd_role": {
          "en": "ICD continuously monitors heart rhythm and automatically delivers a defibrillation shock if VF is detected — acting as an internal safety net to prevent sudden cardiac death before resuscitation can be performed",
          "zh": "ICD 持續監測心律，一旦偵測到 VF 即自動發放去顫電擊，在院外無法立即急救的情況下作為預防心因性猝死的內建安全防護"
        },
        "items": [
          {
            "en": "EF ≤ 35% & NYHA Class II-III Heart Failure — severely reduced pumping function increases risk of fatal arrhythmia",
            "zh": "射出分率 ≤ 35% 且 NYHA 第 II-III 級心衰竭 — 心臟泵血功能嚴重下降，致命性心律不整風險高"
          },
          {
            "en": "Prior MI with EF ≤ 30% — scarred myocardium from infarction creates arrhythmogenic substrate for VF",
            "zh": "心肌梗塞後射出分率 ≤ 30% — 梗塞後疤痕心肌形成易誘發 VF 的致心律不整基質"
          },
          {
            "en": "Inherited Channelopathies (Long QT, Brugada, CPVT) — ion channel mutations predispose to spontaneous VF",
            "zh": "遺傳性離子通道病變（Long QT、Brugada、CPVT）— 離子通道基因突變易自發性誘發 VF"
          },
          {
            "en": "Hypertrophic Cardiomyopathy with risk factors — abnormal myocardial architecture promotes re-entrant VF circuits",
            "zh": "肥厚性心肌病變合併猝死風險因子 — 異常心肌結構促進折返性 VF 迴路形成"
          }
        ]
      },
      "goal": {
        "en": "Goal: Prevent sudden cardiac death from VF before it can occur or be treated externally",
        "zh": "目標：在 VF 發生或無法於院外即時急救前，預防心因性猝死"
      }
    },
    "secondary_prevention": {
      "en": "Secondary Prevention (Survivors of VF arrest)",
      "zh": "次級預防（VF 心臟驟停存活者）",
      "goal": {
        "en": "Goal: Reduce VF Recurrence and prevent sudden cardiac death",
        "zh": "目標：減少 VF 復發，預防心因性猝死"
      },
      "strategies_title": {
        "en": "Management Strategies for Secondary Prevention",
        "zh": "次級預防的治療策略"
      },
      "strategies": [
        {
          "en": "ICD Implantation (Class I recommendation) — automatically detects and terminates recurrent VF episodes via internal shock, essential since survivors are at high risk of repeat arrest",
          "zh": "植入式心律去顫器（ICD）— Class I 建議；自動偵測並以內部電擊終止復發 VF，因存活者再次心臟驟停風險極高"
        },
        {
          "en": "Antiarrhythmic Therapy (Amiodarone, Sotalol) — chronic oral therapy to suppress arrhythmic triggers and reduce VF recurrence frequency",
          "zh": "抗心律不整藥物治療（Amiodarone、Sotalol）— 長期口服以抑制心律不整誘因，降低 VF 復發頻率"
        },
        {
          "en": "Beta-blockers — reduce sympathetic nervous system triggers that can precipitate VF",
          "zh": "β 受體阻斷劑 — 減少可誘發 VF 的交感神經觸發因素"
        },
        {
          "en": "Treatment of Underlying Heart Disease — addressing root cause (e.g., revascularization, HF optimization) reduces arrhythmic substrate",
          "zh": "治療潛在心臟疾病 — 針對根本原因治療（如血管重建、心衰竭優化）以減少致心律不整基質"
        },
        {
          "en": "Electrolyte Optimization — maintain K⁺ ≥ 4.0 mEq/L and Mg²⁺ ≥ 2.0 mg/dL to stabilize myocardial electrical activity",
          "zh": "電解質優化 — 維持 K⁺ ≥ 4.0 mEq/L 及 Mg²⁺ ≥ 2.0 mg/dL，以穩定心肌電氣活動"
        }
      ]
    },
    "antiarrhythmic_therapy": {
      "en": "Antiarrhythmic Medications for Long-term VF Prevention (Chronic Oral Therapy)",
      "zh": "用於長期預防 VF 的抗心律不整藥物（慢性口服治療）",
      "note": {
        "en": "These agents are used chronically to reduce recurrent VF episodes — NOT for acute VF termination",
        "zh": "此處藥物用於長期減少 VF 復發，而非用於急性 VF 發作的即時終止"
      },
      "agents_title": {
        "en": "Medications",
        "zh": "藥物"
      },
      "agents": [
        {
          "drug": "Amiodarone",
          "efficacy": {
            "en": "Most effective for long-term VF suppression; also used IV acutely in ACLS",
            "zh": "長期抑制 VF 最有效；急性期亦可靜脈注射用於 ACLS"
          }
        },
        {
          "drug": "Sotalol",
          "efficacy": {
            "en": "Moderate long-term efficacy; risk of QT prolongation and Torsades de Pointes (TdP)",
            "zh": "中等長期效果；有 QT 延長及尖端扭轉型心室頻脈（TdP）風險"
          }
        },
        {
          "drug": "Beta-blockers",
          "efficacy": {
            "en": "Reduces sympathetic triggers; adjunct therapy, not standalone VF prevention",
            "zh": "減少交感神經觸發；為輔助治療，非單獨預防 VF 的首選"
          }
        }
      ]
    }
  }
}
